Evolent Health (EVH) saw its stock price plummet by 5.33% in pre-market trading on Friday, following a series of price target cuts by multiple Wall Street analysts. The healthcare sector company faced a significant setback as analysts reassessed its valuation amid near-term challenges.

Leading the downgrades, TD Cowen slashed its price target for Evolent Health to $8 from $14, signaling a substantial reduction in the firm's expectations for the stock. This was followed by BTIG, which lowered its target price to $16 from $20, further contributing to the negative sentiment surrounding the company.

While specific reasons for the downgrades were not immediately clear, the coordinated nature of these price target cuts suggests that analysts may be concerned about Evolent Health's near-term growth prospects or potential headwinds in the healthcare sector. Despite these challenges, some analysts, like Charles Rhyee from TD Cowen, maintained a positive long-term outlook on the company, hinting at potential strategic growth opportunities that could materialize in the future.